Krones Ag Adr (KRNTY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Up to you, Olaf. So I think let's start. Good afternoon and a warm welcome from my side. My name is Olaf Scholz, head of investor relations here at Crohn's. We have presented this morning our preliminary figures for the fiscal year 25. So Crohn's continued profitable growth in 25 and we forecast also a further revenue and profitable growth for 26. Next to me is Christoph Kleng and Uto Anders. They will give you more details about these figures and also additional information. And we will also talk about the 26 targets. After the presentation, you will have the opportunity to ask questions. I think you also know how the Q&A session works. Please use the function Raise Your Hand in Teams or send me just a short email and then I will hand over to you. Additionally, please be reminded that this meeting will not be recorded and that it is also not allowed to record the meeting. Please also deactivate any functions of recording at Teams. So, I think we can start with the presentation, and I will hand over to Christoph Bank, CEO of Croze. Yeah, Olaf, thank you. Warm welcome, ladies and gentlemen, on behalf of Uta and myself, to our preliminary figures for 2025, and of course, to how we see 2026, and looking forward then, of course, answering your questions. I will skip as always I would say the beginning of the slides because this has been actually working as a summary for you that you can see all in a condensed way and you even over the numbers I will skip because we go in detail anyway I can say if you see here the numbers at the end of 2025 and seeing the results we are extremely happy Before I continue, I want to extend a big thank you to the Crohn's team globally. So 21,000 people having made this success possible because, you know, we're dealing with 160 countries aro...